SCHEMBL30836835

CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(OC(C)(C)C)cc1)NC(=O)[C@H](COC(C)(C)C)NC(=O)[C@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)OC(C)(C)C)NC(=O)[C@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)OC(C)(C)C)NC(=O)[C@H](C)NC(=O)[C@H](Cc1cn(C(c2ccccc2)(c2ccccc2)c2ccccc2)cn1)NC(=O)C(F)(F)F)[C@@H](C)OC(C)(C)C)[C@@H](C)OC(C)(C)C)C(C)C)C(=O)N[C@@H](CCC(=O)OC(C)(C)C)C(=O)NCC(=O)N[C@@H](CCC(=O)NC(c1ccccc1)(c1ccccc1)c1ccccc1)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)O

nearest known ligand 0.40

Predicted protein targets (top 6)

	gene	UniProt	supporting neighbours	confidence
▸	OPRM1	P35372	7/20	0.40

▸	OPRD1	P41143	7/20	0.40

▸	OPRK1	P41145	7/20	0.40

▸	TFPI	P10646	1/20	0.38

▸	GLP1R	P43220	10/20	0.38

▸	SCTR	P47872	1/20	0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL30175817	0.96	OPRM1 (0.40)	OPRM1OPRD1OPRK1TFPIGLP1R
SCHEMBL30884234	0.95	OPRM1 (0.44)	OPRM1OPRD1OPRK1GLP1RSCTR
SCHEMBL30343345	0.94	OPRM1 (0.45)	OPRM1OPRD1OPRK1GLP1RSCTR
SCHEMBL31255808	0.93	OPRM1 (0.43)	OPRM1OPRD1OPRK1GLP1RSCTR
SCHEMBL31461628	0.90	OPRM1 (0.45)	OPRM1OPRD1OPRK1GLP1RSCTR
SCHEMBL31175849	0.90	OPRM1 (0.39)	OPRM1OPRD1OPRK1GLP1RSCTR
SCHEMBL30175807	0.89	REN (0.39)	OPRM1OPRD1OPRK1TFPIGLP1R
SCHEMBL30882172	0.88	OPRM1 (0.44)	OPRM1OPRD1OPRK1TFPIGLP1R
SCHEMBL31461629	0.88	GLP1R (0.43)	OPRM1OPRD1OPRK1GLP1RSCTR
SCHEMBL31210152	0.87	PSMB8 (0.37)	OPRM1OPRD1OPRK1GLP1RSCTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20260103498-A1	METHOD FOR PREPARING LIRAGLUTIDE	BACHEM HOLDING AG (CH)	2026-04-16	—	—	US	disclosed
EP-4345104-B1	METHOD FOR PREPARING LIRAGLUTIDE	BACHEM HOLDING AG (CH)	2024-08-28	—	—	EP	disclosed
EP-4345104-A1	METHOD FOR PREPARING LIRAGLUTIDE	Bachem Holding AG (CH)	2024-04-03	—	—	EP	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20260103498-A1	METHOD FOR PREPARING LIRAGLUTIDE	GLP1R, IAPP, VIP	OPRM1 2309/4885OPRD1 3623/4885OPRK1 3819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.